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Barbital (B)-dependent rats were prepared by the B-Admixed Food method (DAF method).
The B-dependent rats were grouped according to the following 5 states: G-I, B-dependent state; G-II, B-withdrawan state; G-III, cross-administration of nitrazepam (NZP) following B-withdrawal; G-IV, cross-administration of chlorpromazine (CPZ) following B-withdrawal; and G-V, cross-administration of phenytoin following B-withdrawal. The controls were comprised of naive rats (G-VI) and naive rats dosed in the same manner as the dependent rats. The brain 5-HT synthesis rate and the brain 5-hydraxyindole acetic acid (5-HIAA) elimination were measured at 44 to 48 hr after B-withdrawal in all groups (when withdrawal convulsion was still persisting in the B withdrawn rats of the G-II group). The brain 5-HT synthesis rate was elevated significantly (P<0.001 ) in the rats with persistent B-withdrawal convulsion (G-ll) as compared with that in the B-dependent rats (G-I). Cross-administration of nitrazepam caused the elevation of 5-HT synthesis rate with B-withdrawal to be inhibited to the dependent level in parallel with the inhibition of B-withdrawal signs.
On the other hand, CPZ and phenytoin, which inhibit B-withdrawal convulsion slightly, failed to recover completely the 5-HT turnover rate during B-withdrawal. From these results, it is obvious that the elevation of the brain 5-HT synthesis rate with B-withdrawal plays an important role in eliciting B-withdrawal convulsion.
There have been studies on the relation ships between the threshold value for acute convulsion induced by electric shock or with pentetrazol (PTZ) and the brain monoamines and in the rats with the brain 5-HT content reduced by the administration of p-chlorophenylalanine (PCPA; a 5-HT synthesis inhibitor), the threshold for PTZ convulsion was low (6) . There is also a report (1) indicating that DA plays a principal role in the convulsion.
However, there are varying opinions on what causes the con vulsion, depending on the convulsion model, animal species or animal strain used. There are a number of papers about the variations in brain monoamines in acute or chronic application (7) or after withdrawal of alcohol (8) (9) (10) (11) (12) (13) (14) (15) , but only few papers on barbiturate dependence (16). By observing B-with drawal convulsion and changes in brain catecholamines with application of a-methyl p-tyrosine (a MT) during B-withdrawal, Morgan et al. (17) noted that changes in these parameters were in no way correlated with each other. From the viewpoint of drug dependence, no studies have been made on the reversibility of withdrawal signs, i.e., whether the neuron activities that have changed with B-withdrawal will recover to the pretreatment level on recovery of barbital withdrawal signs or in parallel with the inhibition of B-withdrawal signs with the cross-application of a drug of the same type.
In an investigation of the relationships of drug dependence to changes in the brain monoamines, it is essential to characterize the changes in monoamines in the non withdrawn dependent, the withdrawn, and the cross-administered state with other drugs. Tagashira et al. (18, 19) had been successful in providing a drug dependence model in rats exposed to barbiturates by the DAF (Drug Admixed Food) method. This model is similar to the durg dependence in man or large animals such as dogs and monkeys with respect to changes in withdrawal signs with the passage of time, their severities and durations. The DAF method, as a model for sedative hypnotic dependence with high reproducibility, but with less individual difference and variations, can be applied not only for screening of drug dependence liability, but also for studing the mechanism of drug dependence formation and of studying the mechanism of drug dependence formation and of elimination of withdrawal signs. This study was made to investigate the relation ship between canges in brain serotonin metabolism and the evolvement of withdrawal signs at the stage during which convulsion persised during B withdrawal.
MATERIALS AND METHODS
Male Sprague-Dawley rats (supplied from Tokyo Laboratory Animals Co., Tokyo) were used which weighed 100 to 120 g at the start of the study. There rats were given free access to food and drinking water, housed in individual cages in a room with the light turned on at 8:00 and turned off at 20:00, and air-conditioned to maintain room temper ature (22±2°C) and a relative humidity of 55±5%.
Barbital (B) and nitrazepam (NZP) were administered as mixtures with a powder feed (CA-1, Japan Clea, Tokyo). (18), foods containing B at 2 different con centrations were simultaneously provided in each cage.
Foods containing 0.5 and 1 mg of B per g of food were provided during the first 4 days; those containing 1 and 2 mg/g, on days 5-10, those containing 2 and 4 mg/g, on days 11 to 16, those containing 4 and 6 mg/g, on days 17 to 26, and those contain ing 6 and 8 mg/g, on days 27 to 36, so as to gradual increase the amounts of B ingested by the rats. On this dosage schedule, severely B-dependent rats were produced. Effects of cross-application of test drugs on B-withdrawal signs: When B was with drawn from the B-dependent rats at 9:00 a.m.
(by means of replacing the drug-admixed foods with a normal food), withdrawal signs such as hyperirritability, muscle fasciculation, tremor, muscle twitching, hyperkinesia and clonic-tonic convulsion developed and persisted between 17 and 48 hr after with drawal.
At 48 hr after withdrawal, the rats were examined for magnitudes of weight loss, and severities, frequencies and durations of convulsion to evalute the severities of withdrawal signs.
The B-dependent rats were divided into the G-I (B-dependent) group, G-II (natural  withdrawal) group, and G-III to V (cross application) groups.
NZP (G-III) was given to completely inhibit B-withdrawal signs, and CPZ (G-IV) and PHT (G-V) were cross administered as the drug to partially suppress B-withdrawal signs including convulsion. NZP was given as a mixture with food containing 1.5 mg of NZP per g (20) from the 0 hr of withdrawal and onward.
CPZ at a dosage of 30 mg/kg was cross-applied orally, 4 times in total, at 5 to 6-hr intervals between 31 and 48 hr of withdrawal.
PHT at a dosage of 40 mg/kg was cross-applied orally 5 times at 6-hr intervals between 9 and 48 hr of withdrawal.
For the measure ment of 5-HT synthesis rate, 20 mg/kg of Tcp (21 ), a monoamine oxidase inhibitor, was applied at 44 to 48 hr of withdrawal when the B-withdrawal signs still persisted. The rats were decapitated before or 1 hr after the dosing, and their brains were assayed for 5-HT and its metabolite, 5-HIAA. The rats on natural withdrawal (G-ll), naive rats (G VI) or naive rats cross-dosed with the drugs on the same schedule as for the cross physical dependence liability test were used as controls.
Assay methods:
A slight modification of the procedure for 5-HT and 5-HIAA deter mination by Perez-Cruet et al. (22) was used.
The rat brains were removed quickly and each was homogenized with 0.1 N hydro chloric acid containing 0.5% ascorbic acid. The homogenate was neutralized with 1 N sodium hydroxide and deproteinized by the addition of 10% zinc sulfate.
The supernatant was transferred into another test tube, saturated with sodium chloride, neutralized with 1 N hydrochloric acid, and washed with 10 ml of benzene to remove indoleacetic acid.
Ten ml of n-butylacetate was added to the product, the mixture was shaken, and centrifuged.
The n-butylacetate layer was used for the determination of 5-HIAA and the water layer for the determination of 5-HT. (Fig. 1) . The dosing of naive rats with NZP (1.5 mg/ g food) resulted in the appearance of generalized muscle relaxation, staggering gaint, ptosis and head shaking from about 12 hr after the dosing and onward. The oral dosing with CPZ and PHT also caused the manifestations of CNS depression, muscle relaxation, ptosis, etc. which were similar to those observed with NZP. Hypothermia and hypokinesia were especially striking with CPZ. The cross-application of NZP during B withdrawal was followed by no rapid weight losses which were seen in the control group on B-withdrawal, and the rats treated with NZP showed the same circadian rhythm of body weight as naive rats (Fig. 1) . This cross-dosing also inhibited the other with drawal signs almost completely.
The cross dosing with CPZ, unlike that with NZP, did not inhibit the weight loss, and the CPZ treated rats exhibited a weight loss pattern similar to that of the controls on B-withdrawal (Fig. 2) . This cross-dosing further inhibited the frequency of withdrawal convulsion, but failed to inhibit vocalization, hyperirritability and tremor. The cross-dosing with PHT inhibited the weight loss to about 7% as compared with the maximum loss of 1 1 % in the controls on B-withdrawal (Fig. 2) . It also partially inhibited the withdrawal signs, with hyperreflexia, tremor and clonic con vulsion still persisting. Chlorpromazine and phenytoin were cross-administered 4 times at 5-6 hr intervals and 5 times at 6 hr intervals, respectively. groups) and the group on natural withdrawal as compared with these parameters in the untreated group. No difference was noted in brain 5-HT and 5-HIAA levels or 5-HT synthesis rate and 5-HIAA elimination between the naive rats in a steady state and the non-withdrawn, dependent rats. The natural withdrawal of B, however, was followed by statistically significant (P<0.05) elevations of both 5-HIAA levels and 5-HT synthesis rate in the MD and SD groups. Also, the brain 5-HIAA elimination decreased (Table 2) . In other words, the cross-dosing with NZP inhibited and recovered the elevated 5-HT synthesis rate and the depressed brain 5 HIAA elimination during B-withdrawal to almost the same level as those in naive or B-dependent rats (Fig. 5) . In comparison, the cross-dosing with CPZ and PHT gave rise to a tendency for the inhibition of the 5-HT synthesis rate which was slight corn pared with that induced with NZP.
DISCUSSION
In a previous paper (24), Tagashira et al. described the effects on B-withdrawal signs of cross-dosing with B, NZP, and 5-HT metabolism-related substances, i.e ., 5 hydroxytryptoph an (5-HT P, a 5-HT precursor), p-chlorophenylalanine (PC PA, a 5-HT synthesis inhibitor) and tranylcy promine (monoamine oxidase inhibitor). They further studied changes in 5-HT and 5-HIAA levels in a steady state with the cross-dosing, and found that the application of tranyl cypromine during B-withdrawal both in mildly and severely dependent rats (25) was followed within 10 min by the appearance of clonic-tonic convulsion in all rats. This lead to the presumption that brain mono amines play an important role in the develop ment of withdrawal convulsion.
The present study was designed to observe changes in brain 5-HT synthesis rate for the purpose of investigating the mechanism of Tcp-induced B-withdrawal convulsion from the aspect of 5-HT metabolism.
It is possible to study whether changes In mildly dependent and withdrawan rats, a significant elevation of 5-HT synthesis rate was also observed upon appearance of convulsion with the tranylcypromine challenge.
Thus, the elevation of 5-HT synthesis rate may probably be related to the elicitation of B-withdrawal convulsion.
In a previous study (24), we found that when 5-HT metabolism was enhanced by the cross-application of 5-HTP (a precursor of 5-HT) during B-withdrawal, the rats on B-withdrawal fell into a sedative, associated with reduced severities of withdrawal con vulsion.
The reduction in 5-HT level with reserpine or PCPA was followed by a tendency for B-withdrawal signs including convulsion to intensify. Because PCPA is known to induce insomnia (26, 27), this tendency may have resulted from the intensi fication of insomnia, one of the B-withdrawal signs, with this agent. 
